LFCR (Lifecore Biomedical) Selling, General, & Admin. Expense: $25.79 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LFCR Lifecore Biomedical Inc LFCR
55 GF Score
Price $4.68
GF Value $6.47
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Lifecore Biomedical Selling, General, & Admin. Expense?

Lifecore Biomedical LFCR -5.55% 55 Selling, General, & Admin. Expense is $25.79 Mil as of Mar. 2026. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.47 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Lifecore Biomedical's selling, general, & admin. expense for the three months ended in Mar. 2026 was $7.92 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was $25.79 Mil.


Lifecore Biomedical  (NAS:LFCR) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Lifecore Biomedical Selling, General, & Admin. Expense Related Terms


Lifecore Biomedical Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Selling, General, & Admin. Expense Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.72 34.66 38.97 40.46 44.05

Lifecore Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.98 8.98 8.90 0.00 7.92

LFCR vs ANIK, DERM, ASRT: Selling, General, & Admin. Expense Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical Selling, General, & Admin. Expense vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Selling, General, & Admin. Expense falls into.


LFCR
55GF Score
Lifecore Biomedical Inc LFCR
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $25.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $25.79 Mil mean?
Lifecore Biomedical (LFCR) has a Selling, General, & Admin. Expense of $25.79 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Lifecore Biomedical and its competitors.
Is Lifecore Biomedical's Selling, General, & Admin. Expense too high?
Lifecore Biomedical's current Selling, General, & Admin. Expense is $25.79 Mil. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Selling, General, & Admin. Expense compare to ANIK and DERM?
Lifecore Biomedical's Selling, General, & Admin. Expense of $25.79 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Lifecore Biomedical and its competitors. Lifecore Biomedical's current Selling, General, & Admin. Expense is $25.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.47, compared to a current price of $4.68 — trading 27.7% below its estimated fair value. The current Selling, General, & Admin. Expense is $25.79 Mil. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Selling, General, & Admin. Expense is $25.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (LFCR) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of $4.68 is trading 27.7% below its estimated GF Value™ of $6.47. GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.

Key valuation signals for LFCR:

  • Selling, General, & Admin. Expense: $25.79 Mil
  • GF Value™: $6.47 vs. price of $4.68 (27.7% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lifecore Biomedical Business Description

Other Exchanges LDE:Germany
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score

Get the complete analysis for LFCR

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.68
Price
$6.47
GF Value